Stock Analysis
- United Kingdom
- /
- Biotech
- /
- AIM:SCLP
Scancell Holdings plc's (LON:SCLP) recent 10.0% pullback adds to one-year year losses, hedge funds owners may take drastic measures
Key Insights
- Institutions' substantial holdings in Scancell Holdings implies that they have significant influence over the company's share price
- The top 6 shareholders own 51% of the company
- Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
A look at the shareholders of Scancell Holdings plc (LON:SCLP) can tell us which group is most powerful. With 38% stake, hedge funds possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
And hedge funds investors saw their holdings value drop by 10.0% last week. This set of investors may especially be concerned about the current loss, which adds to a one-year loss of 25% for shareholders. Hedge funds typically use aggressive strategies that focus on short-term gains. Because of their large stake in Scancell Holdings, they hold a lot of power, and persistent under performance could lead to them influencing management decisions that might diverge from the company's long-term goals.
In the chart below, we zoom in on the different ownership groups of Scancell Holdings.
See our latest analysis for Scancell Holdings
What Does The Institutional Ownership Tell Us About Scancell Holdings?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
Scancell Holdings already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Scancell Holdings, (below). Of course, keep in mind that there are other factors to consider, too.
It would appear that 38% of Scancell Holdings shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Redmile Group, LLC is currently the largest shareholder, with 26% of shares outstanding. Vulpes Investment Management Private Limited is the second largest shareholder owning 11% of common stock, and UBS Asset Management AG holds about 5.1% of the company stock.
We also observed that the top 6 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Scancell Holdings
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our information suggests that Scancell Holdings plc insiders own under 1% of the company. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It appears that the board holds about UK£227k worth of stock. This compares to a market capitalization of UK£92m. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling.
General Public Ownership
The general public, who are usually individual investors, hold a 34% stake in Scancell Holdings. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 5 warning signs for Scancell Holdings you should be aware of, and 2 of them are concerning.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:SCLP
Scancell Holdings
A clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease.